|1.||Borgers, M: 2 articles (01/2009 - 07/2007)|
|2.||Verfaille, C J: 2 articles (09/2007 - 07/2007)|
|3.||Bovenschen, H J: 2 articles (09/2007 - 02/2007)|
|4.||van de Kerkhof, P C M: 2 articles (09/2007 - 02/2007)|
|5.||Mertens, J: 2 articles (09/2007 - 07/2007)|
|6.||Kasimanickam, R: 1 article (04/2014)|
|7.||Kasimanickam, V: 1 article (04/2014)|
|8.||Pavez Loriè, E: 1 article (01/2009)|
|9.||Wouters, L: 1 article (01/2009)|
|10.||Shroot, B: 1 article (01/2009)|
|1.||Psoriasis (Pustulosis Palmaris et Plantaris)
02/01/2007 - "Hence, rambazole might be beneficial in the treatment of plaque psoriasis. "
09/01/2007 - "R115866 merits further evaluation to optimize its clinical efficacy and safety profile in moderate to severe plaque-type psoriasis."
09/01/2007 - "To explore the efficacy, safety and tolerability of systemic R115866 in patients with moderate to severe plaque-type psoriasis. "
09/01/2007 - "Oral R115866 in the treatment of moderate to severe plaque-type psoriasis."
02/01/2007 - "The dynamics of epidermal proliferation, keratinization, lesional T-cell subsets and cells expressing natural killer (NK)-receptors in plaque psoriasis were assessed during treatment with rambazole, as part of a phase IIa open-label clinical trial. "
07/01/2007 - "Oral R115866 in the treatment of moderate to severe facial acne vulgaris: an exploratory study."
07/01/2007 - "The current data indicate that treatment with oral R115866 1 mg once daily for 12 weeks in patients with moderate to severe facial acne vulgaris is efficacious and well tolerated and merits further investigation."
07/01/2007 - "To explore the efficacy, safety and tolerability of systemic R115866 in male patients with moderate to severe facial acne vulgaris (at least 15 papules and/or pustules and at least two nodulocystic lesions). "
11/01/2008 - "Phase II clinical trials of an oral formulation of talarozole in patients with psoriasis and with acne, and a phase I clinical trial of a topical formulation have been completed. "
07/01/2007 - "By virtue of this property, and the proven positive effects of retinoids in the treatment of acne, R115866 could potentially be a useful drug for acne. "
04/01/2014 - "The objective of the study was to investigate the regulation of meiosis-associated and male germ cell-related genes, stimulated by retinoic acid gene 8 (STRA8), synaptonemal complex protein 3 (SYCP3), dosage suppressor of mck1 (DMC1), doublesex and mab-3 related transcription factor 1 (DMRT1) and deleted in azoospermia-like (DAZL) following exogenous administration of retinoic acid (RA) and after the modulation of endogenous RA by a cytochrome P450, family 26, subfamily B, polypeptide 1 inhibitor (CYP26B1-I; R115866) in an in vitro testis model. "
|5.||Ventricular Heart Septal Defects (Ventricular Septal Defect)
12/01/2006 - "Blockade of Cyp26 function in the chick embryo using R115866, a specific inhibitor of Cyp26 enzyme function, resulted in a dose-dependent phenocopy of the Tbx1 null mouse including loss of caudal pa and pharyngeal arch arteries (paa), small otic vesicles, loss of head mesenchyme and, at later stages, DiGeorge Syndrome-like heart defects, including common arterial trunk and perimembranous ventricular septal defects. "
|1.||Tretinoin (Retinoic Acid)
|2.||Cytochrome P-450 Enzyme System (Cytochrome P450)
|3.||cytochrome P-450 CYP26B1 (CYP26B1)
|6.||Hepatitis B Vaccines (Hepatitis B Vaccine)
|10.||Fibroblast Growth Factor 1 (FGF-1)